Sharekhan recommended Hold rating on Cadila Healthcare with a target price of Rs 275 in its research report dated August 09, 2019.
Sharekhan's research report on Cadila Healthcare
Cadila’s quarterly performance adjusted for one-offs was better than our expectation. Moraiya facility classified as OAI by USFDA to remain an overhang until resolved.
We maintain our Hold rating on the stock with marginally downward revised PT of Rs. 275. Biologics and vaccines business to propel growth and profitability from FY2021E.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Subscribe to Moneycontrol Pro and gain access to curated markets data, trading recommendations, equity analysis, investment ideas, insights from market gurus and much more. Get Moneycontrol PRO for 1 year at price of 3 months at 289. Use code FREEDOM.